Third-line therapy and beyond for patients with advanced/metastatic non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Corral Jaime, Jesus [1 ]
Gonzalez de la Pena, Miriam [1 ]
Alonso, Miriam [1 ]
Sanchez Gastaldo, Amparo [1 ]
Dolores Mediano, Maria [1 ]
Amerigo, Marta [1 ]
Enrique Robles, Carlos [1 ]
机构：
[1] Hosp Univ Virgen Rocio, Seville, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19160
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase II study of enzastaurin as second- or third-line treatment of non-small cell lung cancer (NSCLC)
    Bepler, G.
    Oh, Y.
    Burris, H.
    Cleverly, A.
    Lahn, M.
    Herbst, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [32] A phase II study of enzastaurin as second- or third-line treatment of non-small cell lung cancer (NSCLC)
    Oh, Y.
    Herbst, R.
    Burris, H.
    Cleverly, A.
    Lahn, M.
    Bepler, G.
    EJC SUPPLEMENTS, 2006, 4 (12): : 35 - 35
  • [33] Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer
    de Marinisa, Filippo
    Grossi, Francesco
    ONCOLOGIST, 2008, 13 : 14 - 20
  • [34] Efficacy and Toxicity of Pemetrexed as a Third-line Treatment for Non-small Cell Lung Cancer
    Sun, Jong-Mu
    Lee, Keun-Wook
    Kim, Jee Hyun
    Kim, Yu Jung
    Yoon, Ho Il
    Lee, Jae-Ho
    Lee, Choon-Taek
    Lee, Jong Seok
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (01) : 27 - 32
  • [35] Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer
    Shao, Yu-Yun
    Shau, Wen-Yi
    Lin, Zhong-Zhe
    Chen, Ho-Min
    Kuo, Raymond
    Yang, James Chih-Hsin
    Lai, Mei-Shu
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (01) : 106 - 114
  • [36] Approval Summary: Erlotinib Maintenance Therapy of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Cohen, Martin H.
    Johnson, John R.
    Chattopadhyay, Somesh
    Tang, Shenghui
    Justice, Robert
    Sridhara, Rajeshwari
    Pazdur, Richard
    ONCOLOGIST, 2010, 15 (12): : 1344 - 1351
  • [37] Clinical Investigation of the Efficacy and Safety of Anlotinib with Immunotherapy in Advanced Non-Small Cell Lung Cancer as Third-Line Therapy: A Retrospective Study
    Yang, Shengjie
    Zhang, Wenjie
    Chen, Qing
    Guo, Qisen
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 10333 - 10340
  • [38] Prevalence and effectiveness of first-, second-, and third-line systemic therapy in a cohort of unselected patients with advanced non-small cell lung cancer
    Zietemann, V.
    Duell, T.
    LUNG CANCER, 2011, 73 (01) : 70 - 77
  • [39] Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Tzekova, V.
    Cebotaru, C.
    Ciuleanu, T. E.
    Damjanov, D.
    Ganchev, H.
    Kanarev, V.
    Stella, P. J.
    Sanders, N.
    Pover, G.
    Hainsworth, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Docetaxel (Taxotere®) as first-line therapy of advanced non-small cell lung cancer (NSCLC)
    Manegold, C
    ONKOLOGIE, 2003, 26 : 26 - 32
12345